



A SURESH G KARE Enterprise

INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2010

(Rs. In Lacs)

Sr.No	Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year Ended 31.03.2010 (Unaudited)	Year ended 31.03.2009 (Audited)
1	(a) Sales and Income from Operations	11,003	8,580	40,236	35,526
	Less : Excise Duty	116	81	402	462
	Net Sales and Income from Operations	10,887	8,499	39,834	35,064
	(b) Other Operating income	158	142	483	338
	Total	11,045	8,641	40,317	35,402
2	Expenditure :				
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	(374)	344	(634)	(513)
	(b) Consumption of raw materials	4,804	2,921	15,536	12,376
	(c) Purchase of traded goods	732	490	2,522	3,094
	(d) Employees cost	1,487	1,298	5,642	4,794
	(e) Depreciation	338	300	1,210	1,116
	(f) Research & Development Expenses	297	234	1,022	923
	(g) Other Expenditure	2,838	2,542	10,425	9,768
	(h) Total	10,122	8,129	35,723	31,558
3	Profit from Operations before Other Income, Interest and Exceptional Items	923	512	4,594	3,844
4	Other Income	1	1	16	55
5	Profit before Interest and Exceptional Items	924	513	4,610	3,899
6	Interest	72	129	291	585
7	Profit after Interest but before Exceptional Items	852	384	4,319	3,314
8	Exceptional Items	-	-	-	-
9	Profit from Ordinary Activities before tax	852	384	4,319	3,314
10	Tax Expenses - Current	145	48	732	370
	- Deferred	51	(20)	132	108
	- Fringe Benefit Tax	-	12	-	93
	- Prior Year	(22)	-	(22)	(31)
	- MAT Credit	(145)	(48)	(732)	(370)
11	Net Profit from Ordinary Activities after tax	823	392	4,209	3,144
12	Extraordinary Items	-	-	-	-
13	Net Profit for the period	823	392	4,209	3,144
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	26,616
16	Earning Per Share (EPS) - Not Annualised - Rs.				
	(a) Basic and diluted EPS before Extraordinary Items	6.70	3.19	34.26	25.59
	(b) Basic and diluted EPS after Extraordinary Items	6.70	3.19	34.26	25.59
17	Public shareholding				
	- No of Shares	48,57,636	50,29,231	48,57,636	50,29,231
	- % of Shareholding	39.53	40.93	39.53	40.93
18	Promoters and promoters group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	8,200	8,200	8,200	8,200
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	0.11	0.11	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	0.07	0.07	0.07
	b) Non-encumbered				
	- Number of shares	74,20,878	72,49,283	74,20,878	72,49,283
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	99.89	99.89	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.40	59.00	60.40	59.00

Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.1.2010 : Nil, Received during quarter : Nil, Resolved: Nil, Pending as on 31.03.2010 : Nil.
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 26th April 2010 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai
Date : April 26, 2010

Suresh G. Kare
Chairman & Managing Director